Breast imaging-reporting and data system (BI-RADS) assessment category 3
Citation, DOI and article data
BI-RADS 3 is an intermediate category in the breast imaging reporting and data system. A finding placed in this category is considered probably benign, with a risk of malignancy of > 0% and ≤ 2%4.
BI-RADS 3 should not be utilized in the screening setting. It should be reserved for the diagnostic setting, such as when patients are recalled from screening for additional views (ie, following BI-RADS 0) or when patients present with a palpable lump.
The BI-RADS Atlas, fifth edition, contains three mammographic findings that should be categorized as BI-RADS 3 4,6:
- grouped round calcifications
- circumscribed, round or oval mass without calcification
- focal asymmetry without calcification or architectural distortion
The following sonographic findings may be categorized as BI-RADS 3 6:
- complicated cyst with uniform low-level echoes
- microlobulated or oval mass composed of clustered microcysts (although BI-RADS 2 may be appropriate if the appearance is classic 7)
- hypoechoic mass, circumscribed, oval, parallel, without posterior features or with minimal posterior enhancement
- hyperechoic mass with central hypoechoic to anechoic components and surrounding edema consistent with, but not diagnostic of, fat necrosis
- refraction shadowing without an associated mass
- architectural distortion thought to be due to postsurgical scar
BI-RADS 3 carries a management recommendation of short-term follow-up. The recommendation should be for the modality or modalities that best demonstrated the initial finding. While follow-up protocols differ across practices, a common schedule is at 6, 12, and 24 months. Once stability is documented for at least two, and at most three years, the finding can be downgraded to BI-RADS 2 (benign). If the finding develops suspicious features such as growth, non-circumscribed margins, or suspicious calcification morphology, then a BI-RADS 4 or BI-RADS 5 classification should be considered.
- 1. Raza S, Chikarmane SA, Neilsen SS et-al. BI-RADS 3, 4, and 5 lesions: value of US in management--follow-up and outcome. Radiology. 2008;248 (3): 773-81. doi:10.1148/radiol.2483071786 - Pubmed citation
- 2. Hall FM. Malignancy in BI-RADS category 3 mammographic lesions. Radiology. 2002;225 (3): 918-9. doi:10.1148/radiol.2253020507 - Pubmed citation
- 3. Raza S, Goldkamp AL, Chikarmane SA et-al. US of breast masses categorized as BI-RADS 3, 4, and 5: pictorial review of factors influencing clinical management. Radiographics. 2010;30 (5): 1199-213. doi:10.1148/rg.305095144 - Pubmed citation
- 4. ACR. ACR BI-RADS Atlas. AMER COLLEGE OF RADIOLOGY. ISBN:155903016X. Read it at Google Books - Find it at Amazon
- 5. Lee KA, Talati N, Oudsema R, Steinberger S, Margolies LR. BI-RADS 3: Current and Future Use of Probably Benign. (2018) Current radiology reports. 6 (2): 5. doi:10.1007/s40134-018-0266-8 - Pubmed
- 6. Messinger J, Crawford S, Roland L, Mizuguchi S. Inappropriate use of BI-RADS Category 3: Learning from mistakes. (2019) Applied Radiology. 48(1):28-33. Appl Radiol
- 7. Heather I. Greenwood, Amie Y. Lee, Iryna V. Lobach, Bianca M. Carpentier, Rita I. Freimanis, Loretta M. Strachowski. Clustered Microcysts on Breast Ultrasound: What Is an Appropriate Management Recommendation?. (2017) American Journal of Roentgenology. 209 (6): W395-W399. doi:10.2214/AJR.17.17813 - Pubmed